Coffee breakthrough

July 2005
Gut;Jul2005, Vol. 54 Issue 7, p1044
Academic Journal
The article focuses on researches related to consumption of coffee and caffeine and its physiological effects. Researcher C.E. Ruhl and J.E. Everhart analyzed data from the Third National Health and Nutrition Examination Survey to investigate whether coffee intake is protective in subjects at risk for liver injury. Researcher U. Gelatti and colleagues compared lifetime coffee consumption of 250 patients with hepatocellular carcinoma with 500 controls hospitalized for reasons other than liver or alcohol related diseases and neoplasms.


Related Articles

  • Perking Up Defense Against Liver Cancer.  // Tufts University Health & Nutrition Letter;Apr2005, Vol. 23 Issue 2, p7 

    Presents the results of a study conducted in Japan on the effect of coffee drinking on the risk of developing liver cancer. Reason for the inability of researchers to compare the effect of decaffeinated and high-test coffee; Potential role of antioxidants found in coffee in inhibiting liver...

  • Caffeine Buzz Greater in Small Doses.  // hfm (Healthcare Financial Management);Mar2007, Vol. 61 Issue 3, p24 

    The article reports on the study conducted by the researchers from Rush University Medical Center on the effects of drinking caffeine in the U.S. The researchers administered a low dose of caffeine hourly to a group of men. They have found that the level of caffeine in their bloodstreams...

  • Good news for fans of the black stuff.  // New Scientist;2/26/2005, Vol. 185 Issue 2488, p21 

    The article informs that drinking coffee might have at least one health benefit: reducing your risk of liver cancer. A team led by Manami Inoue of the National Cancer Center in Tokyo analysed a 10-year study of 90,000 people in Japan. They found that middle-aged and elderly people who drank...

  • Time to Quit Coffee? Meyers, Cheryl // Natural Solutions;May2010, Issue 125, p77 

    The article provides guidelines in minimizing coffee intake and suggests several caffeine-free coffee alternatives.

  • Research brief: Coffee cuts liver cancer risk.  // GP: General Practitioner;4/29/2005, p6 

    The article cites a study on liver cancer. The study found that drinking coffee reduces the risk of liver cancer by up to 70 per cent. The researchers looked at 250 patients with liver cancer and a control group of 500 patients hospitalized for a reason other than cancer or liver disease. They...

  • Radioactive beads combat liver cancer. Davies, Anne // New Scientist;1/5/91, Vol. 129 Issue 1750, p24 

    Announces that doctors in the US claim to have improved the survival rates for patients with inoperable liver cancers by the use of radiotherapy from the inside. How James Andrews and his colleagues at the University of Michigan's hospital in Ann Arbor deliver the radioactive element;...

  • Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.  // Journal of Translational Medicine;2011, Vol. 9 Issue 1, p120 

    The article presents a research conducted on mechanism-related circulating proteins as biomarkers for clinical result in patients with unresectable hepatocellular carcinoma receiving sunitinib. Under the research, patients with advanced HCC received a dose of sunitinib 50 mg/day administered...

  • Helicobacter Species Ribosomal DNA Recovered from the Liver Tissue of Chinese Patients with Primary Hepatocellular Carcinoma. Xue-Gong Fan; Xiao-Ning Peng; Yan Huang; Yakoob, Javed; Zhi-Ming Wang; Yong-Ping Chen // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p1555 

    Examines 16S ribosomal DNA of Heliobacter species in liver tissue specimens obtained from patients with hepatocellular carcinoma. Percentage of patients found to be positive for Heliobacter species; Direct sequencing of four 16S rDNA fragments from positive polymerase chain reaction samples;...

  • Brivanib conferred no survival benefit in HCC.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p22 

    The article presents the results of the double blind international study as of October 2013, which showed that the investigational drug brivanib has no positive effects on the survival among patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization.


Read the Article


Sign out of this library

Other Topics